Abstract
Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.
Publication types
-
Letter
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Benzamides
-
Creatine Kinase / metabolism*
-
Female
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
-
Lipid Metabolism / drug effects*
-
Male
-
Metabolic Diseases / chemically induced*
-
Metabolic Diseases / metabolism
-
Middle Aged
-
Phosphates / metabolism*
-
Piperazines / administration & dosage
-
Piperazines / adverse effects*
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects*
-
Retrospective Studies
Substances
-
Antineoplastic Agents
-
Benzamides
-
Phosphates
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate
-
Creatine Kinase